Skip to main content
SpringerLink
Log in

Schwerpunkt "Zelluläre Therapien"

CAR-T-Zellen: Neue Therapien, neue Nebenwirkungen

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literaturverzeichnis

  1. Hill JA et al. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596

  2. Neelapu SS et al. Axicabtagen-Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-44

  3. Schuster SJ et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56

  4. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55

  5. Shimabukuro-Vornhagen A et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56

  6. Yakoub-Agha I et al. [Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)]. Bull Cancer. 2019;106(1S):S102-9

  7. Gust J et al. Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020;11:577027

  8. Garcia Borrega J et al. In the eye of the storm: Immune-mediated toxicities associated with car-t cell therapy. Hemasphere. 2019;3(2):e191

  9. Santomasso BD et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8(8):958-71

  10. Parker KR et al. Article Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for Article Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020;183(1):126-142.e17

  11. Rice J et al. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. Curr Treat Options Neurol. 2019;21(8):40

  12. Wang M et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331-42

  13. Wudhikarn K et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020;10(8):79

  14. Park JH et al. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis. 2018;67(4):533-40

  15. Hill JA et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121-30

  16. Mikkilineni L et al. Infectious Complications Associated with CAR T-Cell Therapy. Blood. 2019;134(Supplement_1):4449

  17. Maude SL et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48

  18. Jacobson CA et al. Axicabtagen-Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020;38(27):3095-106

  19. Morgan RA et al. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-51

  20. Diaconu I et al. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther. 2017;25(3):580-92

  21. Tasian SK et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129(17):2395-407

  22. Locke FL et al. Long-term safety and activity of Axicabtagen-Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42

Download references

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Schwerpunkt Internistische Intensivmedizin, Klinikum der Universität Köln, Köln, Deutschland

    Katrin Heindel &  Jorge Garcia Borrega

  2. Klinik für Inn. Medizin Univ. Klinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland

    Boris Böll

Authors
  1. Katrin Heindel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge Garcia Borrega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boris Böll
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heindel, K., Garcia Borrega, J. & Böll, B. CAR-T-Zellen: Neue Therapien, neue Nebenwirkungen. InFo Hämatol Onkol 24, 20–23 (2021). https://doi.org/10.1007/s15004-021-8615-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8615-9

Search

Navigation